Alzheimer’s Disease Causation and Sequence of Events: The Hidden, Cumulative, Exponentiated Ingredient Inherent in the Degradation Cascade
by csmartskin on Jul 25, 2012
- 691 views
Pfizer and Johnson & Johnson recently concluded and announced on July 23rd, 2012 results of Phase 3 of the clinical trial on a jointly developed drug bapineuzumab. The closely watched experimental ...
Pfizer and Johnson & Johnson recently concluded and announced on July 23rd, 2012 results of Phase 3 of the clinical trial on a jointly developed drug bapineuzumab. The closely watched experimental treatment for Alzheimer’s disease proved ineffective in its first large clinical trial. This utter failure completely debunked a theory about the cause of the disease. One of the principal investigators in the study, Dr. Reisa Sperling, stated “there was no sign of any effect.”
Alzheimer’s disease (AD) is characterized clinically by dementia and pathologically by two hallmark lesions, senile plaques and neurofibrillary tangles. About a quarter century ago these hallmark lesions were purified and their protein constituents identified, precipitating an avalanche of molecular studies as well as substantial optimism about successful therapeutic intervention. In 2010, we now have copious knowledge on the biochemical cascades that produce these proteins, the different modifications and forms in which these proteins exist, and the ability to selectively target these proteins for therapeutic intervention on an experimental basis.
© All Rights Reserved
- Embed Views
- Views on SlideShare
- Total Views